MedTrace Logo

A Study Designed to Evaluate the Pharmacokinetic Profile of Abiraterone

NCT04295161 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2020-03-04

No results posted yet for this study

Summary

A Study in Healthy Male Subjects Designed to Evaluate the Pharmacokinetic Profile of Abiraterone Following Administration of Immediate Release Formulations

Conditions

  • Pharmacokinetics

Interventions

DRUG

Abiraterone Acetate

Abiraterone acetate immediate release formulations

Sponsors & Collaborators

  • Zentiva, k.s.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-06-25
Primary Completion
2019-11-08
Completion
2019-11-08

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04295161 on ClinicalTrials.gov